×
About 81,414 results

ALLMedicine™ Ovarian Cancer Center

Research & Reviews  37,861 results

Precision medicine testing in ovarian cancer: The growing inequity between patients wit...
https://doi.org/10.1016/j.ygyno.2021.04.025
Gynecologic Oncology; Gamble CR, Huang Y et. al.

May 7th, 2021 - Precision medicine technologies have significant impact in the care of patients with ovarian cancer. Compared to affluent patients, socioeconomically vulnerable patients are less likely to have access to this testing. There is little data that dem...

Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal do...
https://doi.org/10.1002/cam4.3903
Cancer Medicine; Jones RL, Herzog TJ et. al.

May 7th, 2021 - As with other alkylating agents, cardiac dysfunction can occur with trabectedin therapy for advanced soft tissue sarcomas (STS) or recurrent ovarian cancer (ROC) where treatment options for advanced disease are still limited. Cardiac safety for tr...

Differences in Sociodemographic Disparities Between Patients Undergoing Surgery for Adv...
https://doi.org/10.1245/s10434-021-10086-y 10.1370/afm.1919 10.1007/s00384-014-1928-5 10.1053/j.seminoncol.2011.05.011 10.1245/s10434-009-0487-4 10.1097/01.sla.0000197702.46394.16 10.1002/bjs.8679 10.1016/S1470-2045(20)30599-4 10.1002/cncr.32529 10.3748/wjg.v18.i39.5489 10.1016/j.soc.2018.02.009 10.1155/2012/541842 10.3978/j.issn.2078-6891.2015.106 10.1002/cncr.24482 10.1097/AOG.0000000000000643 10.1016/j.ygyno.2011.11.025 10.1067/s0002-9378(03)00579-9 10.1200/JCO.2004.00.1297 10.1016/j.ajog.2014.10.1104 10.1016/j.ygyno.2013.08.035 10.1002/cncr.22604 10.1038/sj.bjc.6604298 10.1016/j.ygyno.2017.10.002 10.1016/j.socscimed.2010.03.033 10.1097/AOG.0b013e3182922a17 10.1097/AOG.0000000000002164 10.1245/s10434-020-08781-3 10.1093/jnci/djy221 10.1200/JOP.2014.003293 10.1007/s10865-008-9190-3 10.1146/annurev-soc-073014-112305 10.1158/1055-9965.EPI-09-0305 10.1177/002214650905000301 10.1016/j.socscimed.2013.10.026 10.3322/canjclin.54.2.78 10.1016/j.amjsurg.2020.12.009 10.3978/j.issn.2078-6891.2015.039 10.1200/JCO.2011.37.5527 10.1158/1055-9965.EPI-07-2774 10.1097/DCR.0000000000000684 10.1002/cncr.29253 10.1245/s10434-020-08733-x 10.1038/srep29765 10.1007/s11606-014-3102-8
Annals of Surgical Oncology; Goldberg EM, Berger Y et. al.

May 7th, 2021 - Cytoreductive surgery (CRS) for ovarian cancer with peritoneal metastases (OPM) is an established treatment, yet access-related racial and socioeconomic disparities are well documented. CRS for colorectal cancer with peritoneal metastases (CRPM) i...

Spatial cytotoxic and memory T cells in tumor predict superior survival outcomes in pat...
https://doi.org/10.1002/cam4.3942
Cancer Medicine; Zhang G, Xu Q et. al.

May 6th, 2021 - Although the association between tumor-infiltrating CD3+ T and CD8+ T cells and superior survival in high-grade serous ovarian cancer (HGSOC) has been observed, the different spatial localization of tumor-infiltrating lymphocytes (TILs) possesses ...

Human epididymis protein 4 promotes P‑glycoprotein‑mediated chemoresistance in ovarian ...
https://doi.org/10.3892/mmr.2021.12135
Molecular Medicine Reports; Liu Q, Liu DW et. al.

May 6th, 2021 - The aim of the present study was to investigate the effects of human epididymis protein 4 (HE4) on drug resistance and its underlying mechanisms. The associations among proteins were detected by immunoprecipitation and immunofluorescence assays. T...

see more →

Guidelines  233 results

Breastfeeding Challenges: ACOG Committee Opinion, Number 820.
https://doi.org/10.1097/AOG.0000000000004253
Obstetrics and Gynecology;

Jan 22nd, 2021 - Breastfeeding is associated with a decrease in a woman's risk of breast cancer, ovarian cancer, diabetes mellitus, and hypertensive heart disease. Breastfeeding initiation rates in the United States are increasing, and many women are aware of the ...

ESMO recommendations on predictive biomarker testing for homologous recombination defic...
https://doi.org/10.1016/j.annonc.2020.08.2102
Annals of Oncology : Official Journal of the European Soc... Miller RE, Leary A et. al.

Oct 2nd, 2020 - Homologous recombination repair deficiency (HRD) is a frequent feature of high-grade serous ovarian, fallopian tube and peritoneal carcinoma (HGSC) and is associated with sensitivity to PARP inhibitor (PARPi) therapy. HRD testing provides an oppor...

PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.
https://doi.org/10.1200/JCO.20.01924
Journal of Clinical Oncology : Official Journal of the Am... Tew WP, Lacchetti C et. al.

Aug 13th, 2020 - To provide recommendations on the use of poly(ADP-ribose) polymerase inhibitors (PARPis) for management of epithelial ovarian, tubal, or primary peritoneal cancer (EOC). Randomized, controlled, and open-labeled trials published from 2011 through 2...

Olaparib shows 1-year survival benefit in recurrent ovarian cancer, BRCA mutations
https://www.healio.com/news/hematology-oncology/20200707/olaparib-shows-1year-survival-benefit-in-recurrent-ovarian-cancer-brca-mutations

Jul 6th, 2020 - Overall survival results from SOLO-2 showed patients with recurrent ovarian cancer and germline BRCA mutations added a year of life when treated with olaparib only, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, told Healio.

Patient survival greatly impacted by selection for ovarian cancer relapse surgery
https://www.healio.com/news/hematology-oncology/20200707/patient-survival-greatly-impacted-by-selection-for-ovarian-cancer-relapse-surgery

Jul 6th, 2020 - Studies presented during the ASCO2020 Virtual Scientific Program showed the benefit of validated selection tools in pursuing surgical measures for ovarian cancer relapse, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, told Healio.

see more →

Drugs  133 results see all →

Clinicaltrials.gov  40,677 results

Precision medicine testing in ovarian cancer: The growing inequity between patients wit...
https://doi.org/10.1016/j.ygyno.2021.04.025
Gynecologic Oncology; Gamble CR, Huang Y et. al.

May 7th, 2021 - Precision medicine technologies have significant impact in the care of patients with ovarian cancer. Compared to affluent patients, socioeconomically vulnerable patients are less likely to have access to this testing. There is little data that dem...

Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal do...
https://doi.org/10.1002/cam4.3903
Cancer Medicine; Jones RL, Herzog TJ et. al.

May 7th, 2021 - As with other alkylating agents, cardiac dysfunction can occur with trabectedin therapy for advanced soft tissue sarcomas (STS) or recurrent ovarian cancer (ROC) where treatment options for advanced disease are still limited. Cardiac safety for tr...

Differences in Sociodemographic Disparities Between Patients Undergoing Surgery for Adv...
https://doi.org/10.1245/s10434-021-10086-y 10.1370/afm.1919 10.1007/s00384-014-1928-5 10.1053/j.seminoncol.2011.05.011 10.1245/s10434-009-0487-4 10.1097/01.sla.0000197702.46394.16 10.1002/bjs.8679 10.1016/S1470-2045(20)30599-4 10.1002/cncr.32529 10.3748/wjg.v18.i39.5489 10.1016/j.soc.2018.02.009 10.1155/2012/541842 10.3978/j.issn.2078-6891.2015.106 10.1002/cncr.24482 10.1097/AOG.0000000000000643 10.1016/j.ygyno.2011.11.025 10.1067/s0002-9378(03)00579-9 10.1200/JCO.2004.00.1297 10.1016/j.ajog.2014.10.1104 10.1016/j.ygyno.2013.08.035 10.1002/cncr.22604 10.1038/sj.bjc.6604298 10.1016/j.ygyno.2017.10.002 10.1016/j.socscimed.2010.03.033 10.1097/AOG.0b013e3182922a17 10.1097/AOG.0000000000002164 10.1245/s10434-020-08781-3 10.1093/jnci/djy221 10.1200/JOP.2014.003293 10.1007/s10865-008-9190-3 10.1146/annurev-soc-073014-112305 10.1158/1055-9965.EPI-09-0305 10.1177/002214650905000301 10.1016/j.socscimed.2013.10.026 10.3322/canjclin.54.2.78 10.1016/j.amjsurg.2020.12.009 10.3978/j.issn.2078-6891.2015.039 10.1200/JCO.2011.37.5527 10.1158/1055-9965.EPI-07-2774 10.1097/DCR.0000000000000684 10.1002/cncr.29253 10.1245/s10434-020-08733-x 10.1038/srep29765 10.1007/s11606-014-3102-8
Annals of Surgical Oncology; Goldberg EM, Berger Y et. al.

May 7th, 2021 - Cytoreductive surgery (CRS) for ovarian cancer with peritoneal metastases (OPM) is an established treatment, yet access-related racial and socioeconomic disparities are well documented. CRS for colorectal cancer with peritoneal metastases (CRPM) i...

Spatial cytotoxic and memory T cells in tumor predict superior survival outcomes in pat...
https://doi.org/10.1002/cam4.3942
Cancer Medicine; Zhang G, Xu Q et. al.

May 6th, 2021 - Although the association between tumor-infiltrating CD3+ T and CD8+ T cells and superior survival in high-grade serous ovarian cancer (HGSOC) has been observed, the different spatial localization of tumor-infiltrating lymphocytes (TILs) possesses ...

Human epididymis protein 4 promotes P‑glycoprotein‑mediated chemoresistance in ovarian ...
https://doi.org/10.3892/mmr.2021.12135
Molecular Medicine Reports; Liu Q, Liu DW et. al.

May 6th, 2021 - The aim of the present study was to investigate the effects of human epididymis protein 4 (HE4) on drug resistance and its underlying mechanisms. The associations among proteins were detected by immunoprecipitation and immunofluorescence assays. T...

see more →

News  2,443 results

BRCA1/2 Mutations Raise Risk for Endometrial Cancer, Too
https://www.medscape.com/viewarticle/948530

Apr 1st, 2021 - NEW YORK (Reuters Health) - Women with a BRCA1 or BRCA2 mutation have an increased risk for endometrial cancer (EC), and the greatest risk is for the rare subgroup of serous-like and p53-abnormal endometrial cancers in BRCA1 mutation carriers, acc...

Cytoreduction in Advanced Ovarian Cancer: 'Keep the Status Quo'
https://www.medscape.com/viewarticle/948395

Mar 29th, 2021 - Cytoreductive surgery should be considered for advanced ovarian cancer even if patients do not respond to chemotherapy, according to researchers. A retrospective, case-control study showed that optimal cytoreductive surgery is an independent predi...

NICE Recommends Ovarian Cancer combination Option on Cancer Drugs Fund
https://www.medscape.com/viewarticle/948166

Mar 25th, 2021 - NICE has published draft guidance which recommends olaparib plus bevacizumab for use within the Cancer Drugs Fund (CDF) as an option for maintenance treatment of advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or p...

Rock Musician Turned Med Student Takes Aim at Ovarian Cancer
https://www.medscape.com/viewarticle/947871

Mar 21st, 2021 - When Stephen Harris first met Guns N' Roses, they were unknown and penniless, backing up The Cult on tour. "I used to steal alcohol from our dressing room for them and get them extra guest passes so they could sell them for money," he says. "Once ...

Risk-Reducing Salpingo-Oophorectomy Could Curb Breast Cancer
https://www.medscape.com/viewarticle/947109

Mar 10th, 2021 - NEW YORK (Reuters Health) - In women with pathogenic variants in BRCA1 and BRCA2, risk-reducing salpingo-oophorectomy (RRSO) to help avoid ovarian cancer also appears to reduce breast-cancer risk, particularly within five years of surgery, accordi...

see more →

Patient Education  67 results see all →